Hepatitis C virus infection: the new global epidemic (Q36140671)

12 August 2017

1 reference

title

Hepatitis C virus infection: the new global epidemic (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Adeel A Butt

1

1 reference

PubMed ID

15918781

12 August 2017

language of work or name

1 reference

1 April 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

2

1 reference

12 August 2017

241-249

1 reference

The natural history of hepatitis C virus infection: host, viral, and environmental factors

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C virus infection in healthcare workers: risk of exposure and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

The risk of acquiring hepatitis B or C among public safety workers: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

A study of hepatitis C prevalence in healthcare workers in the West of Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Viral load in HCV RNA-positive pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Risk factors for hepatitis C virus infection in male adults in Rawalpindi-Islamabad, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C: an epidemiological review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C virus infection in the mothers and infants cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Transmission of hepatitis C virus by a cardiac surgeon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Nosocomial outbreak of multiple bloodborne viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Evaluation of abnormal liver-enzyme results in asymptomatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatitis C virus seroconversion rate in established blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.241

21 January 2018

Identifiers

DOI

10.1586/14787210.3.2.241

1 reference

12 August 2017

1 reference

PubMed ID

15918781